Sono-Tek (NASDAQ:SOTK) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 50 percent decrease over earnings of $0.02 per share from the same period last year.
Why Is Cancer Focused Monopar Therapeutics Stock Trading Higher Today?
Monopar Therapeutics Inc (NASDAQ: MNPR) will present data from its ongoing Phase 1b open-label, dose-escalating trial of camsirubicin in patients with advanced soft tissue sarcoma later today at the 2023 Connective Tissue Oncology Society